Related Experiment Video

Updated: Feb 23, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.2K

Two new drugs for rheumatoid arthritis

    Drug and Therapeutics Bulletin
    |September 9, 2017
    PubMed

    Insights

    New targeted synthetic disease-modifying antirheumatic drugs, baricitinib and tofacitinib, offer a new oral treatment for rheumatoid arthritis (RA). This review examines their safety and effectiveness in managing this chronic autoimmune joint disease.

    Area of Science:

    • Rheumatology
    • Immunology
    • Pharmacology

    Background:

    • Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease causing joint inflammation and destruction.
    • RA impacts joints, eyes, heart, and lungs, leading to disability and increased mortality.
    • RA affects nearly 1% of UK adults, over 400,000 individuals.

    Purpose of the Study:

    • To review the evidence for the safety and effectiveness of baricitinib and tofacitinib.
    • To evaluate these new oral targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for RA treatment.

    Main Methods:

    • Literature review of safety and effectiveness data for baricitinib and tofacitinib.
    • Analysis of evidence for targeted synthetic DMARDs in rheumatoid arthritis management.

    Main Results:

    • Baricitinib and tofacitinib represent a new class of oral targeted synthetic DMARDs.
    • Evidence for the safety and effectiveness of these agents in RA is presented.

    Conclusions:

    • Baricitinib and tofacitinib offer a novel oral therapeutic option for rheumatoid arthritis.
    • Further review of evidence supports their role in managing RA.

    More Related Videos

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

    Published on: June 6, 2025

    1.3K
    Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice04:47

    Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

    Published on: October 27, 2023

    1.9K

    Related Concept Videos

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
    591
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
    633
    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

    Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
    558
    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
    565
    Drugs Used in Lower Respiratory Disorders: Overview01:17

    Drugs Used in Lower Respiratory Disorders: Overview

    Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
    Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
    1.3K
    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    289